TDP-43 and Neurodegeneration From Bench to Bedside
Coordonnateurs : Kumar Vijay, Jaiswal Manoj Kumar
Aggregates of the TAR DNA binding protein 43 (TDP-43), are hallmark features of the neurodegenerative diseases Amyotrophic Lateral Sclerosis (ALS) and frontotemporal dementia (FTD), with overlapping clinical, genetic and pathological features. TDP-43 and Neurodegeneration: From Bench to Bedside summarizes new findings in TDP-43 pathobiology and proteinopathies. The book summarizes TDP-43?s structure, function, biology, misfolding, aggregation, pathogenesis and therapeutics. It includes autophagy-mediated therapy, role of stress granule, novel genetic, cell culture-based models, systems biology for precision medicine, development of stem cells and mechanism-based therapies that can target ALS and other related neurodegenerative diseases. This book is written for neuroscientists, neurologists, clinicians, advanced graduate students, drug discovery researchers, as well as cellular and molecular biologists involved in ALS, motor neuron disease (MND) and other neurodegenerative disorders.
2. Structural studies of TDP-43
3. TDP-43 mutations and Amyotrophic Lateral Sclerosis
4. Post translational modifications of TDP-43
5. TDP-43 and Autophagy
6. TDP-43 and Alzheimer Disease
7. TDP-43 and Stress granules
8. Repeat domains in TDP-43
8. Systems Biology of TDP-43
9. Animal models of TDP-43 in ALS
10. Therapeutic modulations of TDP-43
Manoj Kumar Jaiswal, Ph.D., has been non-tenure track faculty (Instructor) in the Department of Psychiatry at Icahn School of Medicine at Mount Sinai, NY, since 2017. He obtained PhD degree at the Georg-August University, Goettingen, Germany, and postdoctoral training at MIT, Cambridge, MA and CNRM, Bethesda, MD. More recently, Dr. Jaiswal is a Research Scientist in the Department of Psychiatry at the Columbia University Medical Center in NY. His current research focuses on studies related to neurodegeneration in ALS, motor neuron disease, brain Injury, and psychiatric disorders. He is a recipient of an NIH Career Development Award and was appointed as a Career Development Fellow and later a Senior Research Fellow at the CNRM in Bethesda, MD where he studied molecular mechanisms of Traumatic Brain Injury (TBI) using 2-photon in-vivo imaging and 3-D microscopy. Dr. Jais
- Reviews TDP-43 structure, folding, function, and pathology
- Identifies TDP-43 role in ALS, FTP, and other neurodegenerative diseases
- Presents a systems and precision biology perspective of TDP-43
- Discusses therapeutics of TDP-43 proteinopathies
- Translates bench research to application bedside
Date de parution : 10-2021
Ouvrage de 270 p.
15.2x22.8 cm
Thèmes de TDP-43 and Neurodegeneration :
Mots-clés :
Acetylation; Aggregates; Aggregation; ALS; Alzheimer's disease (AD)Amyotrophic lateral sclerosis (ALS)Cytoplasmic aggregates; Alzheimer's disease (AD)Amyotrophic lateral sclerosis (ALS)Frontotemporal dementia (FTD)Lewy body dementia (LBD)Parkinson disease (PD)TARDBP; Amyloid; Amyotrophic lateral sclerosis (ALS)C-terminal fragmentation; Amyotrophic lateral sclerosis; Autophagy; C-terminal domain; Cysteine oxidation; Disordered regions; EWS; Frontotemporal dementia (FTD)Frontotemporal lobar degeneration with TDP-43-positive inclusions (FTLD-TDP)Phosphorylation; Frontotemporal dementia (FTD)Pharmacological interventions and drug discovery; Frontotemporal lobar degeneration; FUS; Hsp104Neurodegeneration; Neurodegenerative diseases; Neurotherapeutics; Nonmammalian models; N-terminal domain; Oxidative stress; Prion; Protein interaction networks; Protein-protein interaction network; Randomized clinical trial (RCT)Repeats; RNA recognition Motifs; RNA-binding protein; Spatiotemporal expression; Structure; TAF15TDP-43TAR DNA-binding protein 43TDP-43Transactive response DNA-Binding protein 43 (TDP-43)Ubiquitination